Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI) — RIBS VI  

Coronary In-stent Restenosis Clinical Trial

Official title: Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis

Status Not yet recruiting

Clinical Trial Summary

Treatment of patients with in-stent restenosis (ISR) remains a challenge. This study will assess the efficacy of Bioresorbable Vascular Scaffolds (BVS) (Abbott Vascular) in the treatment of patients suffering from ISR.

Clinical Trial Description

Treatment of patients with ISR remains a challenge. Currently both drug-eluting stents (DES) and drug-coated balloons (DCB) are considered as the strategies of choice in this setting. However, data on the value of BVS in patients with ISR is scarce. BVS are very effective to inhibit neointimal proliferation and they avoid the need of implanting a new permanent metal layer. Accordingly, currently, there is a major interest to elucidate the potential value of BVS in patients with ISR.

This prospective Spanish multicenter study will assess the clinical and angiographic outcome of patients with ISR treated with BVS. BVS will be implanted in selected patients (fulfilling inclusion and exclusion criteria) presenting with either BMS-ISR or DES-ISR. Care will be paid to ensure device optimization. Angiographic follow-up will be obtained at 6-9 months. A centralized angiographic corelab will be used to provide QCA measurements. Clinical follow-up will be also obtained at 1 year and then yearly. Clinical events will be adjudicated by an independent Clinical Event Committee. ;

Related Conditions & MeSH terms

• Coronary In-stent Restenosis

• NCT number: NCT02672878
• Study type: Interventional
• Source: Spanish Society of Cardiology
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: April 2014
• Completion date: December 2020